%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-03-08T11:56:15-05:00
2016-03-08T11:56:28-05:00
2016-03-08T11:56:28-05:00
Adobe InDesign CC 2015 (Windows)
uuid:3a664171-d802-48de-b0ee-914e1f0a5e00
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:2ee42813-187b-ab41-bc09-c57a93725508
proof:pdf
xmp.iid:c6bf8977-9f15-b543-8e81-c50f45e63dbd
xmp.did:37af59fe-b837-2f41-b2cd-2c9f787df019
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2015 (Windows)
/
2016-03-08T11:56:15-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
16 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6 (atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.025 Tc 10 0 0 10 36 736.2775 Tm
[(marginally effective drug for a non-life-threatening condition)-25 ( )]TJ
0 -1.212 TD
[(in the face of substantial and unnecessary uncertainty about)-25 ( )]TJ
0 -1.212 TD
[(its dangers. W)86 (omen with distressing sexual desire problems)-25 ( )]TJ
0 -1.212 TD
[(need good treatments. W)74 (e all need a new drug approval)-25 ( )]TJ
T*
[(process that delivers good decisions based on adequate)-25 ( )]TJ
0.025 Tw 0 -1.212 TD
(evidence\224\()Tj
/T1_1 1 Tf
0 Tw (JAMA Intern Med)Tj
/T1_0 1 Tf
[( Published online Feb. 29, 2016.)-25 ( )]TJ
0.025 Tw 0 -1.212 TD
(doi:10.1001/jamainternmed.2016.0073\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 36 635.3002 Tm
[(T)175 (reating Gout with Oral Steroids)]TJ
/T1_0 1 Tf
-0.025 Tc 10 0 0 10 36 623.178 Tm
[(Oral steroids are an effective option for treating acute gout,)-25 ( )]TJ
0 -1.212 TD
[(according to a new study from Hong Kong. More than 400)-25 ( )]TJ
-0.002 Tw 0 -1.212 TD
[(patients with acute gout were randomized to indomethacin or)-25 ( )]TJ
0 Tw T*
[(prednisolone and followed for 2 weeks. Of the 376 patients)-25 ( )]TJ
0 -1.212 TD
[(who completed the study)92 (, the reductions in mean pain scores)-25 ( )]TJ
0 -1.212 TD
[(were similar)111 (, but indomethacin was associated with signi\037)]TJ
0 Tc (-)Tj
-0.025 Tc T*
(cantly more minor adverse events \(19% vs 6%; )Tj
/T1_1 1 Tf
0 Tc (P)Tj
/T1_0 1 Tf
-0.025 Tc 20.184 0 Td
[( < 0.001\).)-25 ( )]TJ
-20.184 -1.212 Td
[(The authors concluded prednisolone is an effective and safe)-25 ( )]TJ
T*
[(\037rst-line option for the treatment of acute gout. This supports)-24.9 ( )]TJ
0 -1.212 TD
[(the American College of Rheumatology\222)74 (s recent guideline on)-25 ( )]TJ
0 -1.212 TD
[(gout management that recommends oral corticosteroids in)-25 ( )]TJ
T*
(addition to nonsteroidal anti-in\036ammatory drugs and col)Tj
0 Tc (-)Tj
-0.025 Tc 0 -1.212 TD
[(chicine as \037rst-line options for treatment of acute gout. This)-24.9 ( )]TJ
0 -1.212 TD
(study strengthens that recommendation, providing a treat)Tj
0 Tc (-)Tj
-0.025 Tc T*
(ment option for those with renal insuf\037ciency of gastrointes)Tj
0 Tc (-)Tj
-0.025 Tc 0 -1.212 TD
(tinal disease \()Tj
/T1_1 1 Tf
(Ann Intern Med)Tj
/T1_0 1 Tf
[( Published online Feb. 23 2016.)-25 ( )]TJ
0.025 Tw 0 -1.212 TD
(doi:10.7326/M14-2070\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 36 400.9789 Tm
[(A Secondary P)17.7 (revention Against )]TJ
13.118 0 Td
( )Tj
-13.118 -1.152 Td
(Cardiovascular Events?)Tj
/T1_0 1 Tf
-0.025 Tc 10 0 0 10 36 372.7346 Tm
[(Could pioglitazone \(Actos\) be useful as secondary prevention)-25 ( )]TJ
T*
[(against cardiovascular events, even in non-diabetic patients?)-25 ( )]TJ
0 -1.212 TD
[(The answer may be yes, according to a new study of nearly)-25 ( )]TJ
0 -1.212 TD
[(3900 patients with insulin resistance but not diabetes and)-25 ( )]TJ
T*
[(a recent history of ischemic stroke or transient ischemic)-25 ( )]TJ
0 -1.212 TD
[(attack \(TIA\). Patients were randomized to pioglitazone \(45)-25 ( )]TJ
0 -1.212 TD
[(mg daily\) or placebo and followed for nearly 5 years. The)-25 ( )]TJ
T*
[(primary outcome, fatal or nonfatal stroke or myocardial)-25 ( )]TJ
27 44.84 Td
[(infarction, occurred in 9% of the pioglitazone group and)-25 ( )]TJ
T*
[(11.8% of the placebo group \(hazard ratio [HR], 0.76; 95%)-25 ( )]TJ
0 -1.212 TD
(con\037dence interval [CI], 0.62-0.98; )Tj
/T1_1 1 Tf
0 Tc (P)Tj
/T1_0 1 Tf
-0.025 Tc 15.133 0 Td
[( = 0.007\). Diabetes)-25 ( )]TJ
-15.133 -1.212 Td
[(developed in 3.8% of the pioglitazone group and 7.7% of the)-25 ( )]TJ
0 -1.212 TD
(placebo group \(HR, 0.48; 95% CI, 0.33-0.69; )Tj
/T1_1 1 Tf
0 Tc (P)Tj
/T1_0 1 Tf
-0.025 Tc 19.661 0 Td
[( < 0.001\).)-25 ( )]TJ
-19.661 -1.212 Td
[(There was no difference in all-cause mortality)92 (, although)-25 ( )]TJ
T*
[(pioglitazone was associated with greater frequency of weight)-25 ( )]TJ
0 -1.212 TD
[(gain exceeding 4.5 kg, edema, and bone fractures requiring)-25 ( )]TJ
0 -1.212 TD
(surgery or hospitalization. The authors suggested that in pa)Tj
0 Tc (-)Tj
-0.025 Tc T*
[(tients without diabetes but with insulin resistance along with)-25 ( )]TJ
0 -1.212 TD
[(a history of ischemic stroke or TIA, pioglitazone reduced the)-25 ( )]TJ
0 -1.212 TD
[(risk of stroke or myocardial infarction compared to placebo)-25 ( )]TJ
0 Tc T*
(\()Tj
/T1_1 1 Tf
-0.025 Tc 0.308 0 Td
(N Engl J Med)Tj
/T1_0 1 Tf
( Published online Feb. 17, 2016. doi:10.1056/)Tj
-0.308 -1.212 Td
[(NEJMoa1506930\). An accompanying editorial says, \223it has)-25 ( )]TJ
0 -1.212 TD
[(taken two decades to show that an insulin sensitizer decreases)-24.9 ( )]TJ
0 -1.212 TD
[(vascular events in patients selected for insulin resistance.\224)-25 ( )]TJ
T*
[(However)111 (, the editorialist also suggested these patients were)-25 ( )]TJ
T*
[(highly selected, and there are many caveats before clinicians)-25 ( )]TJ
0 -1.212 TD
(rush to prescribe pioglitazone for secondary prevention \()Tj
/T1_1 1 Tf
0 Tc (N )Tj
-0.025 Tc 0 -1.212 TD
(Engl J Med)Tj
/T1_0 1 Tf
( Published online Feb. 17, 2016. doi:10.1056/)Tj
0.025 Tw T*
(NEJMe1600962\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 306 465.5898 Tm
[(R)17.6 (eport: P)17.9 (rescriptions for Hydrocodone-)]TJ
( )Tj
0 -1.152 TD
(containing Combination Drugs Drop)Tj
/T1_0 1 Tf
-0.01 Tc 10 0 0 10 306 437.3455 Tm
[(The switch of hydrocodone-containing combination drugs)-10 ( )]TJ
0 -1.212 TD
[(from Schedule III to the more restrictive Schedule II in)-9.9 ( )]TJ
T*
(October 2014 signi\037cantly reduced the number of pre)Tj
0 Tc (-)Tj
-0.01 Tc 0 -1.212 TD
[(scriptions \037lled for these drugs, according to a new study)92 (.)-10 ( )]TJ
0 -1.212 TD
[(Prescriptions for the combinations, including V)37 (icodin and)-10 ( )]TJ
T*
(Norco, dropped even prior to the restriction, but compar)Tj
0 Tc 24.001 0 Td
(-)Tj
-0.01 Tc -24.001 -1.212 Td
[(ing the 12 months prior to rescheduling to the 12 months)-10 ( )]TJ
T*
(after saw a dramatic 22% reduction in hydrocodone com)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(bination prescriptions and a 16% reduction in the number)-10 ( )]TJ
0 -1.212 TD
[(of pills dispensed. The inability to re\037ll Schedule II drugs)-9.9 ( )]TJ
0 -1.212 TD
(accounted for 74% of the decrease. Non-hydrocodone opi)Tj
0 Tc (-)Tj
-0.01 Tc -0.003 Tw T*
(oid prescriptions increased 4.9% in the same period \()Tj
/T1_1 1 Tf
0.01 Tw [(JAMA)-9.9 ( )]TJ
0 Tw T*
(Intern Med)Tj
/T1_0 1 Tf
( Published online Jan. 25, 2016. doi:10.1001/)Tj
0.01 Tw 0 -1.212 TD
(jamainternmed.2015.7799\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 306 251.5129 Tm
[(FD)17.4 (A Actions)]TJ
/T1_0 1 Tf
-0.01 Tc 10 0 0 10 306 239.3907 Tm
(The Senate has con\037rmed )Tj
/T1_2 1 Tf
(Robert Califf)Tj
/T1_0 1 Tf
[(, MD, as the new)-10 ( )]TJ
0 -1.212 TD
[(FDA commissioner)111 (. Dr)111 (. Califf, a cardiologist, was previ)]TJ
0 Tc (-)Tj
-0.01 Tc T*
[(ously on the faculty of the Duke Medical School as vice)-10 ( )]TJ
0 -1.212 TD
[(chancellor for clinical and translational research. More)-10 ( )]TJ
0 -1.212 TD
[(recently)92 (, he was the FDA)123 (\222)74 (s deputy commissioner for medi)]TJ
0 Tc (-)Tj
-0.01 Tc T*
(cal products and tobacco.)Tj
0 -2.424 TD
(The FDA has approved brivaracetam as adjunctive treat)Tj
0 Tc (-)Tj
-0.01 Tc 0 -1.212 TD
(ment for partial onset seizures in patients )Tj
/C2_0 1 Tf
0 Tc <0074>Tj
/T1_0 1 Tf
-0.01 Tc 18.156 0 Td
[( 16 years of)-10 ( )]TJ
-18.156 -1.212 Td
[(age. The drug is an analogue of the already-available)-10 ( )]TJ
0 -1.212 TD
[(antiepileptic drug levetiracetam. Approval was based on)-10 ( )]TJ
0 -1.212 TD
[(three clinical trials of 1550 participants that showed the)-10 ( )]TJ
0 -1.212 TD
[(drug was effective in reducing the frequency of seizures.)-10 ( )]TJ
T*
[(Common side effects include drowsiness, dizziness, fatigue,)-10 ( )]TJ
T*
[(and gastrointestinal symptoms. The drug also comes with)-10 ( )]TJ
T*
[(a medication guide for patients regarding depression and)-10 ( )]TJ
0 -1.212 TD
[(suicidal thoughts. Brivaracetam is marketed as Briviact. )20 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_1 1 Tf
0 Tc 23.881 0 Td
<0084>Tj
0 0 0 1 k
/GS0 gs
/T1_3 1 Tf
-0.01 Tc 7 0 0 7 40.75 269 Tm
(PHARMACOLOGY WATCH)Tj
/T1_4 1 Tf
0 Tc 6 0 0 6 127.892 269 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -15.754 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2016 AHC Media, L\
LC.)-10 ( )]TJ
/T1_5 1 Tf
0.01 Tw 8 0 0 8 40.75 252 Tm
(Editor)Tj
/T1_6 1 Tf
0 Tw 0 -1.25 TD
(William T. Elliott, MD, FACP)Tj
0 Tc 12.43 0 Td
( )Tj
/T1_4 1 Tf
-0.01 Tc -12.43 -1.25 Td
(Medical Director, Pharmacy, Northern California Kaiser Permanente)Tj
0 Tc 29.24 0 Td
( )Tj
-0.01 Tc -29.24 -1.25 Td
[(Assistant Clinical Professor of Medicine,)-10 ( )]TJ
0 Tc 17.455 0 Td
( )Tj
-0.01 Tc -17.455 -1.25 Td
(University of California, San Francisco)Tj
/T1_5 1 Tf
T*
(Executive Editor:)Tj
/T1_4 1 Tf
( Leslie Coplin)Tj
/T1_5 1 Tf
T*
(Associate Managing Editor:)Tj
/T1_4 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 180.5 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10 ( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10 ( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation Council)-9.9 ( )]TJ
0 -1.167 TD
[(for Continuing Medical Education guidelines, Dr. Elliott \(editor\), Ms.\
Coplin \(executive)-10 ( )]TJ
T*
[(editor\), and Mr. Springston \(associate managing editor\) report no fin\
ancial relationships)-10 ( )]TJ
0 -1.167 TD
(relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 233.75 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
BT
0 0 0 1 k
/GS0 gs
/T1_5 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_4 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: jonathan.springston@ahcmedia.com)Tj
0 -1.167 TD
(Website: AHCMedia.com)Tj
0 -1.917 TD
[(Address Correspondence to: AHC Media, One Atlanta)-10 ( )]TJ
0 -1.167 TD
[(Plaza, 950 East Paces Ferry Road NE, Suite 2850, Atlanta,)-9.9 ( )]TJ
T*
[(GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
44.685 73.418 70.72 32.443 re
W n
/GS1 gs
q 1 0 0 1 52.0285 92.6745 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 70.4899 86.0851 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 88.2162 88.5766 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 95.8269 88.8489 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 103.1923 88.6991 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
106.664 91.463 1.675 -6.63 re
106.664 84.833 m
108.448 93.314 m
108.448 92.824 108.08 92.416 107.495 92.416 c
106.936 92.416 106.569 92.824 106.569 93.314 c
106.569 93.832 106.95 94.227 107.508 94.227 c
108.08 94.227 108.434 93.832 108.448 93.314 c
f
q 1 0 0 1 113.6622 88.0729 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
endstream
endobj
25 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
9 0 obj
<>
endobj
24 0 obj
<>
endobj
26 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
10 0 obj
<>
endobj
11 0 obj
<>
endobj
12 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
13 0 obj
<>
endobj
46 0 obj
<>
endobj
47 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆